Selank Co

Research compound, not FDA-approved

Selank is a registered Russian medicine and an American research chemical. The molecule is identical. The evidence never left Russia.

Fifty-seven selank papers are indexed in PubMed. Twenty-six are written in Russian. Exactly one carries an author affiliation outside Russia, and it is a review article rather than a study, which puts the count of original non-Russian selank research at zero. Five human studies exist, all Russian, 244 people in total, and not one of their abstracts states a dose. We counted all of it ourselves and published the script that did the counting.

  • 0original selank studies from a non-Russian institution, out of 57 papers indexed
  • 26of the 57 selank-titled papers are published in Russian
  • 6human studies in the evidence table, every one of them Russian
  • 26studies in the graded evidence table, species labeled on every row
  • 40fetch-verified citations, 95 percent peer-reviewed or government

Online care, from intake to delivery

Selank nasal spray care, made simple

Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Selank nasal spray care catalog product image
Compounded nasal sprayPrepared after approval
Catalog image. Dispensed product and packaging may vary by pharmacy.

Your care plan includes

Everything you need to get started

From$125.10per month
Licensed providerMedical reviewIf prescribedTreatment includedAt no added costDiscreet shippingWhen you need itOrder support
Choose your planChange or cancel future refills anytime
Due today$152.10then monthly

Encrypted checkout provider review required shipping included

  1. 01
    Choose your planSelect the supply and refill preference that works for you.
  2. 02
    Complete your intakeShare your health history in our private, secure flow.
  3. 03
    Provider reviewIf appropriate, your prescription is prepared and shipped.

Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.

Key facts

  • StatusResearch compound, not FDA-approved
  • Human PK studiesNone publishedsource
  • Human half-lifeNever measuredsource
  • Human bioavailabilityNever measured, by any route including nasalsource
  • MetabolismDegraded in plasma to TKPRP, TKP, RP and GP (rat, tritium label)source
  • Brain exposureExamined in rat brain tissue after intranasal dosing; no numeric values reportedsource
  • Route differenceIn mice, intranasal and intraperitoneal dosing altered different receptor systems, attributed by the authors to pharmacokineticssource
  • Commonly misquotedPublished half-lives are leu-enkephalin's, not selank'ssource
  • ClassSynthetic heptapeptide; tuftsin analog (tuftsin plus Pro-Gly-Pro)Chemical referencesource
  • SequenceThr-Lys-Pro-Arg-Pro-Gly-ProChemical referencesource
  • Molecular weight751.9 (C33H57N11O9)Chemical referencesource
  • US statusNot FDA approved for any use; no Drugs@FDA recordRegulatory recordsource
  • FDA compoundingSelank acetate (TP-7) listed as nominated but withdrawn, with an immunogenicity concernRegulatory recordsource
  • Russian statusListed as a registered Russian peptide drug, classified anxiolytic (peer-reviewed source; not verified at the register)Review or guidelinesource
  • Selank-titled PubMed papers57, of which 26 are published in RussianInternal measurementsource
  • Non-Russian original studies0 in the PubMed index; the one non-Russian affiliation is a reviewInternal measurementsource
  • Human studies5 total: 4 in patients, 1 imaging study in healthy volunteersHuman trialsource
  • People studied244 across all studies with a stated count; largest single study 70Internal measurementsource
  • Randomized controlled efficacy trialsNone located in any readable indexAbsence of evidencesource
  • Registered trials0 on ClinicalTrials.govRegistry recordsource
  • Human pharmacokineticsNone published: no half-life, clearance or bioavailability for any routeAbsence of evidencesource
  • Established human doseNone. No human study abstract states a doseAbsence of evidencesource
  • Long-term safetyNo long-term study, toxicology report or adverse-event surveillance locatedAbsence of evidencesource
  • SportNot named on the 2026 WADA list; unclear status under the S0 catch-allRegulatory recordsource

Read the full Selank monograph

Browse by topic

Everything on Selank, organized the way you research it.

All guides

47 in-depth, individually cited guides.

Evidence 13 guides

Safety 13 guides

Comparisons 8 guides

Dosing 8 guides

We will tell you if anyone outside Russia ever studies this

One short email if the evidence actually changes. Given the last thirty years, we do not expect to email you often.

Free. No spam, unsubscribe anytime. Your address is used for this brief and nothing else.

Start provider review